TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

02 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

27 May 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

25 May 2021 16:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2021 Financial Results

06 May 2021 16:01:02 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

27 Apr 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2021 Financial Results

26 Apr 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

01 Mar 2021 16:01:01 By Nasdaq GlobeNewswire

Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease

25 Feb 2021 08:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

22 Feb 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy

18 Feb 2021 16:30:00 By Nasdaq GlobeNewswire